The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients

Persistent viral replication resulting in ongoing cytomegalovirus (CMV) viremia despite adequate therapy is difficult to manage and associated with negative outcomes. We report a case series of kidney transplant recipients receiving adjunctive letermovir in combination with valganciclovir for refractory CMV.

[1]  N. Khardori,et al.  Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report. , 2021, Transplantation proceedings.

[2]  G. Gupta,et al.  Letermovir prophylaxis in solid organ transplant—Assessing CMV breakthrough and tacrolimus drug interaction , 2021, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  F. Thalhammer,et al.  Letermovir for the compassionate therapeutic use of cytomegalovirus infection , 2020, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[4]  T. Berney,et al.  Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient. , 2020, Transplantation.

[5]  C. Strassburg,et al.  Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient , 2020, European journal of case reports in internal medicine.

[6]  Deepali Kumar,et al.  Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients. , 2020 .

[7]  N. Kneidinger,et al.  Letermovir for difficult to treat cytomegalovirus infection in lung transplant recipients , 2020, Pneumologie.

[8]  S. Nathan,et al.  Single‐center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[9]  W. Kraft,et al.  Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil , 2019, Journal of clinical pharmacology.

[10]  A. Humar,et al.  Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice , 2019, Clinical transplantation.

[11]  D. Grewal,et al.  Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis , 2019, Antimicrobial Agents and Chemotherapy.

[12]  S. Chou,et al.  Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  S. Chou,et al.  Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing , 2014, Antimicrobial Agents and Chemotherapy.

[14]  Klemens Budde,et al.  Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[15]  E. Cordero,et al.  Use of High-Dose Ganciclovir for the Treatment of Cytomegalovirus Replication in Solid Organ Transplant Patients With Ganciclovir Resistance-Inducing Mutations , 2013, Transplantation.

[16]  H. Zimmermann,et al.  The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase , 2011, Journal of Virology.

[17]  H. Zimmermann,et al.  First Report of Successful Treatment of Multidrug‐Resistant Cytomegalovirus Disease with the Novel Anti‐CMV Compound AIC246 , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  A. Caliendo,et al.  The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation , 2010, Transplantation.

[19]  J. L. Stern,et al.  Immunomodulatory Properties of a Viral Homolog of Human Interleukin-10 Expressed by Human Cytomegalovirus during the Latent Phase of Infection , 2008, Journal of Virology.